Skip to main content

Hydrochlorothiazide / propranolol Pregnancy and Breastfeeding Warnings

Brand names: Inderide, Inderide LA

Hydrochlorothiazide / propranolol Pregnancy Warnings

Animal studies with hydrochlorothiazide have failed to reveal evidence of fetal harm. Animal studies with propranolol have revealed evidence of neonatal death and embryotoxicity. There are no controlled data in human pregnancy; however, intrauterine growth retardation, small placentas, and congenital abnormalities have been reported in human neonates whose mothers received propranolol during pregnancy. Neonates whose mothers received propranolol at parturition have exhibited bradycardia, hypoglycemia, and/or respiratory depression.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

See references

Hydrochlorothiazide / propranolol Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Yes (hydrochlorothiazide, propranolol)

See references

References for pregnancy information

  1. Product Information. Inderide (hydrochlorothiazide-propranolol). Wyeth-Ayerst Laboratories.

References for breastfeeding information

  1. Product Information. Inderide (hydrochlorothiazide-propranolol). Wyeth-Ayerst Laboratories.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.